Technologies related to NCI

Title
15kD Granulysin for Monocyte Differentiation: A New Immunotherapeutic for Both in vivo and ex vivo Applications
Ref: E-158-2009 | Updated: Oct 10, 2017
Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy
Ref: E-022-2017 | Updated: Jan 8, 2019
Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy
Ref: E-022-2017-0 | Updated: Nov 16, 2017
Immunogenic Peptide from NGEP Protein for Developing Prostate Cancer Vaccines
Ref: E-042-2009 | Updated: Oct 4, 2017
Urine-based Diagnostic Assay for the Early Detection of Cancer
Ref: E-020-2013 | Updated: Oct 6, 2017
Brachyury-directed Vaccine for the Prevention or Treatment of Cancers
Ref: E-055-2011 | Updated: Mar 20, 2018
A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences
Ref: E-067-2017 | Updated: Oct 6, 2017
Multivalent Immunogenic Vaccines for Treating Prostate and Breast Cancer
Ref: E-047-2014 | Updated: Oct 6, 2017
Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors
Ref: E-245-2016 | Updated: Sep 29, 2017
Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery
Ref: E-482-2013 | Updated: Aug 15, 2017
BHD Tumor Cell Line and Renal Cell Carcinoma Line
Ref: E-131-2010 | Updated: Mar 13, 2018
Module to Freeze and Store Frozen Tissue
Ref: E-173-2015 | Updated: Aug 3, 2017
Genetic Assay for Transcription Errors: Methods to Monitor Treatments or Chemicals that Increase the Error Rate of RNA synthesis
Ref: E-237-2016 | Updated: May 4, 2018
Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers
Ref: E-091-2009 | Updated: Jun 29, 2017
Genetic Assay for Transcription Errors: Methods to Monitor Treatments or Chemicals that Increase the Error Rate of RNA synthesis
Ref: E-237-2016 | Updated: May 4, 2018
Use of Heterodimeric IL-15 in Adoptive Cell Transfer
Ref: E-132-2016 | Updated: Sep 7, 2017
Methods of Making Extracellular Vesicles and of Reducing Their Uptake by the Liver
Ref: E-083-2016 | Updated: Apr 17, 2018
Serum Inflammatory Markers as Classifiers of Lung Cancer Mortality
Ref: E-283-2016 | Updated: Jun 16, 2017
Knockout and Conditional Knockout Mice-GPR116
Ref: E-269-2012 | Updated: Apr 23, 2018
Silicone Hydrogel Support Structures that Mimic Tissue Vasculature for Cell Culturing
Ref: E-070-2013 | Updated: Mar 30, 2017
Nanoparticle Platform Using Bacterial Spore Coat Proteins
Ref: E-098-2015 | Updated: Apr 18, 2018
New T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors
Ref: E-153-2016 | Updated: Mar 2, 2017
Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility
Ref: E-065-2015 | Updated: Feb 13, 2017
Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics
Ref: E-025-2015 | Updated: Feb 13, 2017
Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic
Ref: E-130-2016 | Updated: Feb 13, 2017
Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway
Ref: E-278-2014 | Updated: Jan 18, 2017
A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18
Ref: E-137-2004 | Updated: Jul 19, 2018
Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma
Ref: E-291-2015 | Updated: Jul 19, 2018
A549 Cells: Lung Carcinoma Cell Line for Adenovirus
Ref: E-129-2009 | Updated: May 30, 2018
Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase
Ref: E-093-2013 | Updated: Apr 18, 2018
A Gene-Based Prognostic for Hepatocellular Carcinoma Patient Response to Adjuvant Transcatheter Arterial Chemoembolization
Ref: E-101-2016 | Updated: Jan 8, 2019
Device to guide oxygen over cells for photo-oxidation
Ref: E-244-2016 | Updated: Mar 21, 2018
Device for Growing Mammalian Cells on EM Grids
Ref: E-243-2016 | Updated: Dec 20, 2017
Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue
Ref: E-139-2015 | Updated: Jul 19, 2018
Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis
Ref: E-051-2016 | Updated: Apr 6, 2018
Method for Purifying Antibodies
Ref: E-291-2014-0 | Updated: May 26, 2016
Enhancing Adoptive T Cell Therapy Using c-Myb
Ref: E-232-2015-0 | Updated: Nov 4, 2015
Bispecific Chimeric Antigen Receptors to CD22 and CD19 for Treating Hematological Cancers
Ref: E-106-2015-0 | Updated: Aug 22, 2018
T-cell Chimeric Receptors of TSLPR for Diagnosis and Immunotherapy of Cancer
Ref: E-008-2014-0 | Updated: Nov 20, 2014
Chimeric Receptors Targeting CD-19
Ref: E-042-2014-0 | Updated: Oct 28, 2014
Tumor Infiltrating Lymphocytes from Human Papillomavirus-positive Tumors for the Treatment of Cancer
Ref: E-494-2013-0 | Updated: Oct 13, 2015
Chimeric Antigen Receptors to CD276 (B7-H3) for Treatment of Cancer
Ref: E-104-2013-0 | Updated: Aug 22, 2018
Methods for Producing Stem Cell-like Memory T cells for Use in T cell-based Immunotherapies
Ref: E-174-2012-0 | Updated: Oct 13, 2015
Enhanced Cancer Immunotherapy Using microRNA-155
Ref: E-272-2012-0 | Updated: Oct 13, 2015
The First HLA Class II Restricted T Cell Receptor that Recognizes the Cancer Testis Antigen, MAGE-A3
Ref: E-230-2012-0 | Updated: Oct 4, 2018
Mouse-Derived NY-ESO-1 T Cell Receptor for Use in Immunotherapy
Ref: E-105-2012-0 | Updated: Oct 13, 2015
Non-HLA-A2 Restricted Human T Cell Receptors to Treat Broad Cancer Population
Ref: E-266-2011-0 | Updated: Oct 13, 2015
Gas Permeable Flasks to Grow Tumor Infiltrating Lymphocytes (TIL) for More Effective Anti-Cancer Immunotherapy
Ref: E-114-2011-0 | Updated: Oct 13, 2015
Monoclonal Antibodies for Rare Diseases
Ref: E-039-2011-0 | Updated: May 3, 2016
Breakthrough Immunotherapy for Brain Cancer
Ref: E-148-2011-0 | Updated: Nov 7, 2018
Transplant and Autoimmune Therapy Using T-Cells Expressing Programmed Death Ligand-1 (PD-L1)
Ref: E-022-2010-0 | Updated: Oct 9, 2014
Chimeric Anti-human ROR1 Monoclonal Antibodies
Ref: E-097-2009-0 | Updated: Aug 17, 2012
Use of Anthrax Lethal Factor to Treat Cancer and Screening Methods for MAPK Kinase Protease Activity
Ref: E-066-1998-0 | Updated: Nov 20, 2013
Phage Display Plasmids with Improved Expression Properties for Human and Chimeric Nonhuman/Human Fab Libraries
Ref: E-008-2010-0 | Updated: Nov 17, 2009
Fully Human Anti-Human Monoclonal Antibody Helpful in Developing Therapies Against Autoimmune and Infectious Diseases and Cancer
Ref: E-211-2008-0 | Updated: Nov 1, 2008
Biologically Active Macrolides, Compositions and Uses Thereof
Ref: E-203-2000-0 | Updated: Jun 3, 2010
Selenocysteine Mediated Hybrid Antibody Molecules
Ref: E-146-2007-0 | Updated: Dec 1, 2009
New and Improved Chemotherapy Adjuvants: Folate Based Inactivators of O6-alkylguanine-DNA alkyltransferase (alkyltransferase)
Ref: E-200-2007-0 | Updated: Sep 1, 2007
Identification of Anti-HIV Compounds Inhibiting Virus Assembly and Binding of Nucleocapsid Protein to Nucleic Acid
Ref: E-121-2002-0 | Updated: Jun 16, 2010
Cyanovirins and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Use for Microbicide Development
Ref: E-117-1995-3 | Updated: Jun 16, 2010
Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use
Ref: E-025-2006-0 | Updated: Feb 1, 2006
Oligodeoxyribonucleotides Comprising O6-Benzylguanine and Their Use
Ref: E-104-1998-0 | Updated: Dec 16, 2013
Zebularine, A Stable and Orally Active Inhibitor of Cytosine DNA Methyltransferase Capable of Reactivating Dormant Tumor Suppressor and Inhibiting Tumor Growth
Ref: E-081-2001-0 | Updated: Dec 1, 2016
Recombinant Plasmids Containing HIV Reverse Transcriptase
Ref: E-034-1991-0 | Updated: Sep 1, 2005
Antitumor Macrocyclic Lactones / Vacuolar-Type (H+)-ATPase-Inhibiting Compounds and Uses Thereof
Ref: E-244-1997-0 | Updated: Sep 1, 2005
Scytovirin Domain 1 (SD1) Related Polypeptide
Ref: E-180-2005-0 | Updated: Aug 1, 2005
Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using
Ref: E-106-2003-0 | Updated: Aug 1, 2004
Rapamycin Resistant T Cells and Therapeutic Uses Thereof
Ref: E-063-2003-0 | Updated: Aug 1, 2003
Chondropsin-Class Antitumor V-ATPase Inhibitor Compounds, Compositions and Methods of Use Thereof
Ref: E-191-2002-0 | Updated: Jun 14, 2010
Scytovirins and Related Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using Scytovirin
Ref: E-017-2002-0 | Updated: Apr 1, 2003
Grafting of a Murine Antibody Onto a Human Framework
Ref: E-056-2002-0 | Updated: Mar 1, 2003
5-Substituted Derivatives of Conformationally Locked Nucleoside Analogues
Ref: E-249-2000-0 | Updated: Jun 1, 2001
Utilization of Non-Viral Sequences for Minus-Strand DNA Transfer and Gene Reconstitution
Ref: E-134-2000-0 | Updated: Dec 1, 2000
Acylated Oligopeptide Derivatives Having Cell Signal Inhibiting Activity
Ref: E-019-1999-0 | Updated: Jun 1, 1999
A Mutant Of TEV Protease That Is Resistant To Autoinactivation
Ref: E-084-1998-0 | Updated: Feb 1, 1999

Pages

Subscribe to Technologies related to NCI